Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 6/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7281490 | 0.89 | CYP2C19 (0.62) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL44801 | 0.84 | CYP2C19 (1.00) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL11260584 | 0.81 | CYP2C19 (0.72) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4133539 | 0.81 | CYP2C19 (0.72) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5935700 | 0.81 | CYP2C19 (0.72) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL724648 | 0.81 | CYP2C19 (0.72) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1602026 | 0.80 | CYP2C19 (0.55) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL11291081 | 0.79 | CYP2C19 (0.70) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5935770 | 0.78 | CYP2C19 (0.68) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL11537189 | 0.78 | CYP2C19 (0.68) | CYP2C19HPGDUSP2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361253-A1 | STING AGONIST COMPOUNDS | SUTRO BIOPHARMA INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4536672-A1 | STING AGONIST COMPOUNDS | Sutro Biopharma, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119654330-A | STING agonist compounds | 苏特罗生物制药公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2023239675-A1 | STING AGONIST COMPOUNDS | SUTRO BIOPHARMA, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239675-A1 | STING AGONIST COMPOUNDS | SUTRO BIOPHARMA, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-104098650-B | The synthesis and application of the intermediate of Atosiban | 中国医学科学院药物研究所 | 2019-04-09 | — | — | CN | disclosed |
| CN-104098650-A | Synthesis and application of intermediate of atosiban | INST MATERIA MEDICA CAMS | 2014-10-15 | — | — | CN | disclosed |
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ERIKSSON ANDERS | 2009-12-03 | — | — | US | disclosed |
| EP-1732903-B1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| CN-1960979-A | Triazolone derivatives as MMP inhibitors for the treatment of asthma and copd | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | CN | disclosed |
| EP-1732903-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | AstraZeneca AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095362-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2005-10-13 | — | — | WO | disclosed |
| US-4992504-A | Heat resistance, photostability | CIBA-GEIGY CORPORATION (US) | 1991-02-12 | — | — | US | disclosed |
| US-4134918-A | ENZYME INHIBITORS, ANTIBODY INHIBITORS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | MMP9, MMP3, MMP25 | CYP2C19 138/4885HPGD 155/4885USP2 2030/4885 |
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | MMP3, MMP9, MMP25 | CYP2C19 125/4885HPGD 133/4885USP2 1926/4885 |
| US-20250361253-A1 | STING AGONIST COMPOUNDS | STING1, CGAS, MAVS | CYP2C19 4741/4885HPGD 2845/4885USP2 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.